XmAb-808

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug NameXmAb-808

Drug Alias NameXmAb808

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionAnti-CD276Anti-CD28

TargetsCD276 antigenT-cell-specific surface glycoprotein CD28

Therapy Area/IndicationsProstatic Neoplasms, Castration-ResistantCarcinoma, Non-Small-Cell LungOvarian Neoplasms +[10]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesXencor Inc

China Registration ClassN/A

Develop Information

Active CompaniesXencor Inc

Inactive CompaniesN/A

Active IndicationsProstatic Neoplasms, Castration-ResistantCarcinoma, Non-Small-Cell LungOvarian Neoplasms +[10]

Inactive IndicationsN/A

Other Information

ATC CodeN/A